ArticleCellular and molecular life sciences : CMLS2025
The inhibition of ZC3H13 attenuates G2/M arrest and apoptosis by alleviating NABP1 m6A modification in cisplatin-induced acute kidney injury.
Article in Cellular and molecular life sciences : CMLS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed.
- Baicalein Attenuates High Glucose and Sodium Palmitate-Induced Ferroptosis in Cardiomyocytes via the Nrf2/SLC7A11/GPX4 Signaling Pathway.International journal of molecular sciences · 2026Article
- Epitranscriptomic silencing of the ZC3H13/mJournal of experimental & clinical cancer research : CR · 2026Article
- The crucial role of N6-methyladenosine modification in acute kidney injury: mechanisms and therapeutic potential.Frontiers in immunology · 2026Review
- Article
- N6-methyladenosine: a key regulator in ocular disease mechanisms and treatment.Cell death discovery · 2025Review
- METTL14 alleviates sepsis-induced acute kidney injury by targeting Hmox1-mediated ferroptosis through m6A modification.Journal of molecular histology · 2025Article
- Decoding mJournal of translational medicine · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Acute kidney injury (AKI) is a clinical syndrome caused by various etiologies and causes a rapid decline in renal function in a short period of time. The most common internal modification of mRNAs is the N6-methyladenosine (m6A) modification, which is important for controlling gene expressions. However, the role of m6A modification in AKI is largely unknown. Here, we characterized the role of zinc finger CCCH-type containing 13 (ZC3H13), which is a type of m6A methyltransferases, in cisplatin-induced AKI mouse model and a cisplatin-treated human proximal tubular epithelial cell line (HK2 cells). The ZC3H13 knockdown attenuated the G2/M cell cycle arrest and apoptosis in HK2 cells. In the ZC3H13-overexpressed HK2 cells, the opposite was true. In the presence of cisplatin, mice with the AAV9-mediated silencing of ZC3H13 exhibited milder cell cycle arrest, apoptosis, and renal injury. In addition, we identified nucleic acid binding protein 1 (NABP1) as a target of ZC3H13, which was verified by knocking down and overexpressing ZC3H13 in HK2 cells. Moreover, we confirmed that the ZC3H13-mediated m6A modification stabilized NABP1 mRNA and was discriminated by insulin-like growth factor 2 mRNA binding protein 1 (IGF2BP1). In conclusion, ZC3H13 promoted the m6A modification of NABP1 and enhanced its mRNA stability through an IGF2BP1-dependent mechanism. The inhibition of ZC3H13 alleviated the G2/M cell cycle arrest, apoptosis and kidney injury by affecting the expression of NABP1. These results show that the ZC3H13/NABP1 axis is a promising AKI treatment target.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.